Revance Therapeutics, Inc. RVNC
Set alert
3.65 0.00 0.00%
At close · Feb 6
3.65 Day range 3.65
52-week range unavailable
- YTD
- +20.07%
- 1 year
- -39.37%
- Open
- 3.65
- Prev close
- 3.65
- Mkt cap
- 320.48M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.65
- High
- 3.65
- Forward P/E
- -3.23
- Beta
- 0.95
- Short ratio
- 5.20
- Inst. own
- 82.89%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.37
- 200-d avg
- 4.37
- 1y target
- 7.64
Analyst view
Consensus: hold
Hold
Price target (mean) 7.64 +109.2% upside
Now 3.65
- Target (low)
- 3.00
- Target (mean)
- 7.64
- Target (high)
- 25.00
Ratings (0m) 8 1 buy · 7 hold · 0 sell
- Strong buy0
- Buy1
- Hold7
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 9
- 2 months ago 9
- 3 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.40 | -0.40 – -0.40 | -0.6085 | +34.3% | 73.05M | +4.7% | 1 |
| Next quarter | -0.30 | -0.30 – -0.30 | -0.54 | +44.4% | 69.30M | +33.4% | 1 |
| Current year | -1.64 | -1.64 – -1.64 | -3.80 | +56.8% | 263.56M | +12.6% | 1 |
| Next year | -1.01 | -1.35 – -0.67 | -1.64 | +38.4% | 332.74M | +26.3% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Dec 10, 2024 | Mizuho | Maintained | Neutral | Neutral |
| Nov 8, 2024 | Needham | Reiterated | — | Hold |
| Nov 8, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Oct 28, 2024 | Needham | Reiterated | — | Hold |
| Sep 13, 2024 | Barclays | Downgrade | Overweight | Equal-Weight |
| Aug 13, 2024 | Needham | Downgrade | Buy | Hold |
| Aug 12, 2024 | Guggenheim | Downgrade | Buy | Neutral |
| Aug 12, 2024 | William Blair | Downgrade | Outperform | Market Perform |
| Aug 9, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 9, 2024 | Stifel | Maintained | Buy | Buy |
| Aug 9, 2024 | Needham | Reiterated | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 13, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| May 10, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| May 10, 2024 | Mizuho | Maintained | Neutral | Neutral |
| May 10, 2024 | Needham | Maintained | Buy | Buy |
| Mar 1, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |
| Feb 29, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 29, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Feb 29, 2024 | Needham | Maintained | Buy | Buy |
| Feb 23, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 29, 2024 | Barclays | Maintained | Overweight | Overweight |
| Jan 29, 2024 | Mizuho | Downgrade | Buy | Neutral |
| Jan 9, 2024 | Needham | Maintained | Buy | Buy |
| Jan 9, 2024 | Goldman Sachs | Downgrade | Buy | Neutral |
| Nov 22, 2023 | Mizuho | Maintained | Buy | Buy |
| Nov 9, 2023 | Piper Sandler | Maintained | Overweight | Overweight |
| Nov 9, 2023 | Needham | Maintained | Buy | Buy |
| Nov 6, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |